Kinetic properties of monoclonal insulin antibodies. 1986

H Keilacker, and H Dietz, and S Witt, and K P Woltanski, and R Berling, and M Ziegler

We investigated four insulin-specific hybridoma antibodies with respect to their kinetic properties as well as the binding behaviour of some combinations of them. From equilibrium binding data all but one antibodies were shown to bear homogeneous binding sites. They revealed homogeneity of binding sites also by kinetic experiments, thus with high probability being monoclonal. At 0 degree C, two of them showed discrepancies between kinetic and steady state binding data in as much as, at steady state, the measured bound-to-free ratio of tracer insulin was 3-4 times lower than calculated from kinetic data. Thus a simple bimolecular reaction mechanism could possibly not be applicable. Mixing two monoclonal insulin antibodies, neither cooperative nor additive binding to the insulin molecule could be observed but only competitive effects. Especially, no positive cooperativity between two or more antibodies could be detected, which would be able to account for the higher affinity usually observed for polyclonal vs. monoclonal antibodies.

UI MeSH Term Description Entries
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D007075 Immunoglobulin M A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally was called a macroglobulin. Gamma Globulin, 19S,IgM,IgM Antibody,IgM1,IgM2,19S Gamma Globulin,Antibody, IgM
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007330 Insulin Antibodies Antibodies specific to INSULIN. Antibodies, Insulin
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006825 Hybridomas Cells artificially created by fusion of activated lymphocytes with neoplastic cells. The resulting hybrid cells are cloned and produce pure MONOCLONAL ANTIBODIES or T-cell products, identical to those produced by the immunologically competent parent cell. Hybridoma
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

H Keilacker, and H Dietz, and S Witt, and K P Woltanski, and R Berling, and M Ziegler
December 1999, Molecular immunology,
H Keilacker, and H Dietz, and S Witt, and K P Woltanski, and R Berling, and M Ziegler
January 1985, Methods in enzymology,
H Keilacker, and H Dietz, and S Witt, and K P Woltanski, and R Berling, and M Ziegler
January 1985, Pharmacology & therapeutics,
H Keilacker, and H Dietz, and S Witt, and K P Woltanski, and R Berling, and M Ziegler
January 1986, Annales de l'Institut Pasteur. Immunologie,
H Keilacker, and H Dietz, and S Witt, and K P Woltanski, and R Berling, and M Ziegler
September 1987, Diabetes,
H Keilacker, and H Dietz, and S Witt, and K P Woltanski, and R Berling, and M Ziegler
September 2014, The journal of physical chemistry. B,
H Keilacker, and H Dietz, and S Witt, and K P Woltanski, and R Berling, and M Ziegler
June 1982, Cellular immunology,
H Keilacker, and H Dietz, and S Witt, and K P Woltanski, and R Berling, and M Ziegler
January 1995, Methods in molecular biology (Clifton, N.J.),
H Keilacker, and H Dietz, and S Witt, and K P Woltanski, and R Berling, and M Ziegler
October 1981, The Biochemical journal,
H Keilacker, and H Dietz, and S Witt, and K P Woltanski, and R Berling, and M Ziegler
January 1987, Doklady Akademii nauk SSSR,
Copied contents to your clipboard!